Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

AMIT SACHDEV

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1962720797
CMS profile
1045733
Location
EAST LANSING, MI

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$146,935.00

187 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

By paying entity

PY2025 · entire year · sorted by reported total

Page 3 of 4; records 101–150 of 187 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

AMIT SACHDEV

NPI 1962720797 · CMS profile ID 1045733

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

EAST LANSING, MI

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 4; records 101–150 of 187 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1962720797?year=2025&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
AMIT SACHDEV, NPI 1962720797, CMS profile ID 1045733. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 187 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1962720797?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). AMIT SACHDEV, NPI 1962720797, CMS profile ID 1045733. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 187 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1962720797?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
AMIT SACHDEV, NPI 1962720797, CMS profile ID 1045733, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 4; records 101–150 of 187 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1962720797?year=2025&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

187 matching records · $146,935.00 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 187 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 187.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
UCB, Inc. $134.8205/28/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1224777076 CMS
UCB, Inc. $1,300.0005/28/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1224777078 CMS
UCB, Inc. $1,300.0005/28/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1224777080 CMS
Alexion Pharmaceuticals, Inc. $2,450.0005/22/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1202937092 CMS
Alexion Pharmaceuticals, Inc. $2,450.0005/22/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1202967642 CMS
Lundbeck LLC $29.1205/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1251842711 CMS
Janssen Biotech, Inc. $34.3905/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174816972 CMS
CSL Behring $2,970.0005/16/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1232394031 CMS
CSL Behring $18.9505/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1232394033 CMS
CSL Behring $24.9405/16/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1232394035 CMS
CSL Behring $58.1005/16/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1232394037 CMS
CSL Behring $488.9705/16/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1232394039 CMS
CSL Behring $48.0005/16/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1232394041 CMS
Alexion Pharmaceuticals, Inc. $96.8505/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202968888 CMS
Alexion Pharmaceuticals, Inc. $96.8505/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202986768 CMS
CSL Behring $11.7105/14/2025 Education No dispute reported Delay: No
Change: NEW
06/30/2026 1232393981 CMS
HOSPIRA, INC. $19.8605/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1229987570 CMS
UCB, Inc. $10.6205/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1224777074 CMS
TG Therapeutics, Inc. $27.3804/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1226240126 CMS
Merz Pharmaceuticals, LLC $23.4404/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1232556071 CMS
ARGENX US, INC. $1,250.0004/25/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1240424830 CMS
ARGENX US, INC. $21.8804/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1240424838 CMS
ARGENX US, INC. $68.2504/25/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1240424854 CMS
ARGENX US, INC. $4,500.0004/25/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1240424932 CMS
ARGENX US, INC. $1,500.0004/18/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1240432128 CMS
Lilly USA, LLC $13.8704/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186493057 CMS
UCB, Inc. $1,300.0004/14/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1224777072 CMS
CSL Behring $13.0004/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1232393989 CMS
JAZZ PHARMACEUTICALS INC. $21.9704/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234334039 CMS
UCB, Inc. $2,600.0004/08/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1224777070 CMS
Neurelis, Inc. $59.6504/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1219200259 CMS
Takeda Pharmaceuticals U.S.A., Inc. $51.1004/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223939590 CMS
CSL Behring $151.1604/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1232394025 CMS
CSL Behring $258.0604/04/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1232394027 CMS
CSL Behring $300.0004/04/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1232394029 CMS
Otter Pharmaceuticals, LLC $21.3604/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1220933063 CMS
UCB, Inc. $18.4304/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1224777066 CMS
UCB, Inc. $1,300.0004/02/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1224777068 CMS
Averitas Pharma Inc. $16.5803/31/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1248554967 CMS
Alexion Pharmaceuticals, Inc. $175.0003/27/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1202975336 CMS
ARGENX US, INC. $106.5103/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1240424956 CMS
ARGENX US, INC. $420.7203/20/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1240425031 CMS
ARGENX US, INC. $159.1603/20/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1240425043 CMS
ARGENX US, INC. $696.9703/20/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1240425095 CMS
ARGENX US, INC. $445.2703/20/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1240425113 CMS
ARGENX US, INC. $85.0003/20/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1240425117 CMS
Janssen Scientific Affairs, LLC $29.9003/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174172780 CMS
Sarepta Therapeutics, Inc. $83.0003/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223601388 CMS
CATALYST PHARMACEUTICALS, INC. $272.5203/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1253226036 CMS
UCB, Inc. $99.2103/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1224777062 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $20,199.35 34
PY2020 $20,282.22 27
PY2021 $15,315.68 12
PY2022 $60,723.08 64
PY2023 $32,466.89 61
PY2024 $78,397.24 127
PY2025 $146,935.00 187

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $151,296.83 21
PY2024 Principal investigator $91,666.86 21
PY2023 Principal investigator $193,256.62 21
PY2022 Principal investigator $296,028.12 100
PY2021 Principal investigator $318,466.41 244
PY2020 Principal investigator $192,261.06 89
PY2019 Recipient $1,181.36 4
PY2019 Principal investigator $15,602.00 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

21 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,603.58 11/06/2025 Non-covered Recipient Entity
MICHIGAN STATE UNIVERSITY - DEPARTMENT OF NEUROLOGY
A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Remibrutinib in Patients With Generalized Myasthenia Gravis, Followed by an Open-label Extension Phase No dispute reported 06/30/2026 1190306297
Principal investigator 1 ARGENX US, INC. $40,640.00 10/23/2025 Non-covered Recipient Entity
Michigan State University
A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy No dispute reported 06/30/2026 1237152730
Principal investigator 1 ARGENX US, INC. $11,416.00 10/16/2025 Non-covered Recipient Entity
Michigan State University
A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy No dispute reported 06/30/2026 1237152725
Principal investigator 1 Alexion Pharmaceuticals, Inc. $6,902.00 10/14/2025 Non-covered Recipient Entity
BOARD OF TRUSTEES OF MICHIGAN STATE
Long Term, Observational, Registry of Patients With Generalized Myasthenia Gravis Who Have Received Treatment With Complement C5 Inhibition Therapies No dispute reported 06/30/2026 1185540619
Principal investigator 1 SANOFI US SERVICES INC. $36,538.74 08/18/2025 Non-covered Recipient Entity
Michigan State University Center For Bleeding And Cloting Dis
A Phase 3, Doubleblind, Placebocontrolled Study Evaluating Efficacy and Safety of Riliprubart in Participants With Refractory Chronic Inflammatory Demyelinating Polyneuropathy No dispute reported 06/30/2026 1226114720
Principal investigator 1 SANOFI US SERVICES INC. $32,276.00 08/11/2025 Non-covered Recipient Entity
Michigan State University Center For Bleeding And Cloting Dis
PHASE 3 Study in Standard of Care Treated Patients with CIDP (Placebo & IVIG comparator) No dispute reported 06/30/2026 1226114715
Principal investigator 1 ARGENX US, INC. $70.00 08/01/2025 Non-covered Recipient Entity
Michigan State University
A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy No dispute reported 06/30/2026 1237152717
Principal investigator 1 Alexion Pharmaceuticals, Inc. $11,445.00 07/25/2025 Non-covered Recipient Entity
BOARD OF TRUSTEES OF MICHIGAN STATE
A Phase 3, Randomized, Double blind, Placebo controlled, Parallel, Multicenter Study to Evaluate the Safety and Efficacy of ALXN1720 in Adults with Generalized Myasthenia Gravis No dispute reported 06/30/2026 1185540621
Principal investigator 1 ARGENX US, INC. $70.00 07/01/2025 Non-covered Recipient Entity
Michigan State University
A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy No dispute reported 06/30/2026 1237152713
Principal investigator 1 ARGENX US, INC. $70.00 06/01/2025 Non-covered Recipient Entity
Michigan State University
A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy No dispute reported 06/30/2026 1237152705
Principal investigator 1 ARGENX US, INC. $2,147.00 05/22/2025 Non-covered Recipient Entity
Michigan State University
A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy No dispute reported 06/30/2026 1237152722
Principal investigator 1 ARGENX US, INC. $70.00 05/01/2025 Non-covered Recipient Entity
Michigan State University
A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy No dispute reported 06/30/2026 1237152701
Principal investigator 1 Novartis Pharmaceuticals Corporation $2,134.51 05/01/2025 Non-covered Recipient Entity
MICHIGAN STATE UNIVERSITY - DEPARTMENT OF NEUROLOGY
A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Remibrutinib in Patients With Generalized Myasthenia Gravis, Followed by an Open-label Extension Phase No dispute reported 06/30/2026 1190313095
Principal investigator 1 ARGENX US, INC. $548.00 04/01/2025 Non-covered Recipient Entity
Michigan State University
A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy No dispute reported 06/30/2026 1237152697
Principal investigator 1 ARGENX US, INC. $70.00 04/01/2025 Non-covered Recipient Entity
Michigan State University
A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy No dispute reported 06/30/2026 1237152710
Principal investigator 1 ARGENX US, INC. $70.00 03/01/2025 Non-covered Recipient Entity
Michigan State University
A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy No dispute reported 06/30/2026 1237152687
Principal investigator 1 ARGENX US, INC. $104.00 03/01/2025 Non-covered Recipient Entity
Michigan State University
A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy No dispute reported 06/30/2026 1237152693
Principal investigator 1 Eisai Inc. $2,835.00 02/03/2025 Non-covered Recipient Entity
Board of Trustees of Michigan State University
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1244557853
Principal investigator 1 ARGENX US, INC. $70.00 02/01/2025 Non-covered Recipient Entity
Michigan State University
A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy No dispute reported 06/30/2026 1237152684
Principal investigator 1 ARGENX US, INC. $2,147.00 01/21/2025 Non-covered Recipient Entity
Michigan State University
A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy No dispute reported 06/30/2026 1237152719
Principal investigator 1 ARGENX US, INC. $70.00 01/01/2025 Non-covered Recipient Entity
Michigan State University
A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy No dispute reported 06/30/2026 1237152681